Autoimmune Hepatitis clinical trials at UCSF

1 research study open to eligible people

Showing trials for

  • Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)

    open to eligible people ages 18 years and up

    This is a Phase 2a, multi-center, placebo-controlled study in which patients with autoimmune hepatitis will receive zetomipzomib or placebo in addition to standard-of-care for 24 weeks; an optional open-label extension period allows patients to receive zetomipzomib (KZR-616) for an additional 24 weeks of treatment.

    San Francisco, California and other locations

Our lead scientists for Autoimmune Hepatitis research studies include .

Last updated: